Repligen Corp. logo

RGEN

Repligen Corp.

$242.53

Earnings Summary

Revenue
$207.63Mn
Net Profits
$49.86Mn
Net Profit Margins
24.01%
PE Ratio
89.82

Highlights

Revenue:

Repligen Corp.’s revenue jumped 27.41% since last year same period to $207.63Mn in the Q2 2022. On a quarterly growth basis, Repligen Corp. has generated 0.6% jump in its revenue since last 3-months.

Net Profits:

Repligen Corp.’s net profit jumped 37.61% since last year same period to $49.86Mn in the Q2 2022. On a quarterly growth basis, Repligen Corp. has generated 6.17% jump in its net profits since last 3-months.

Net Profit Margins:

Repligen Corp.’s net profit margin jumped 8% since last year same period to 24.01% in the Q2 2022. On a quarterly growth basis, Repligen Corp. has generated 5.54% jump in its net profit margins since last 3-months.

PE Ratio:

Repligen Corp.’s price-to-earnings ratio after this Q2 2022 earnings stands at 89.82.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Repligen Corp. post its latest quarter earnings

EPS Estimate Current Quarter
0.71
EPS Estimate Current Year
0.71

Highlights

EPS Estimate Current Quarter:

Repligen Corp.’s earning per share (EPS) estimates for the current quarter stand at 0.71 - a -1.39% fall from last quarter’s estimates.

EPS Estimate Current Year:

Repligen Corp.’s earning per share (EPS) estimates for the current year stand at 0.71.

Key Ratios

Key ratios of the Repligen Corp. post its Q2 2022 earnings

Earning Per Share (EPS)
0.91
Return on Assets (ROA)
0.06
Return on Equity (ROE)
0.09
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Repligen Corp.’s earning per share (EPS) jumped 15.19% since last year same period to 0.91 in the Q2 2022. This indicates that the Repligen Corp. has generated 15.19% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Repligen Corp.’s return on assets (ROA) stands at 0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Repligen Corp.’s return on equity (ROE) stands at 0.09.

Dividend Per Share (DPS):

Repligen Corp. declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-04-27
0.72
0.92
27.78%
2022-08-02
0.72
0.91
26.39%

Company Information

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Its primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of its manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. it has sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Organisation
Repligen Corp.
Headquarters
Waltham, Massachusetts, US
Employees
1.13K
Industry
Health Technology
CEO
Anthony Hunt